2022-2029 年再生障礙性貧血的全球市場
市場調查報告書
商品編碼
1140738

2022-2029 年再生障礙性貧血的全球市場

Global Aplastic Anemia Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球血液疾病患者數量的增加正在推動市場增長

再生障礙性貧血是一種當身體不能產生足夠的新血細胞時發生的疾病。這種疾病使人容易疲倦,容易出現不受控制的出血和感染。再生障礙性貧血是一種罕見且嚴重的疾病,可在任何年齡發展。再生障礙性貧血可能會突然發生或隨著時間的推移緩慢惡化。再生障礙性貧血可以是中度或嚴重的。再生障礙性貧血可以通過藥物、輸血和乾細胞移植(也稱為骨髓移植)治愈。推動再生障礙性貧血市場增長的主要因素是全球血液病患病率的上升和全球癌症患病率的上升。此外,再生障礙性貧血的技術進步和製藥領域研發活動的增加正在為市場增長創造機會。

地理滲透。

北美地區預計將主導全球再生障礙性貧血市場

本研究按地區分析再生障礙性貧血市場,涵蓋北美、歐洲、亞太地區、南美、中東和非洲等全球市場。

北美將在 2021 年主導全球再生障礙性貧血市場。預計美國在預測期內將代表北美的大幅增長。由於血液病的高發病率,再生障礙性貧血在美國有望出現增長。預計北美在預測期內的價值也將顯著增長。再生障礙性貧血和骨髓疾病患病率的上升預計將推動該地區的市場增長。

在製藥行業的增長以及印度和中國的技術進步的推動下,預計亞太地區再生障礙性貧血市場將在預測期內實現快速增長。由於人口增加和慢性病流行,預計亞太地區再生障礙性貧血市場也將增長。

競爭格局。

對全球再生障礙性貧血市場增長做出貢獻的主要公司包括拜耳公司、諾華公司、輝瑞公司、Ligand Pharmaceuticals Incorporated、Genezyme Corporation、Mylan N.V.、BIOGEN、OTSUKA Pharmaceutical Co. Ltd.、Regen Biopharma Inc.、BiolinRx和別的。領先公司正在為再生障礙性貧血市場的全球增長採用新產品發布和擴張戰略。 2021年8月,輝瑞以54億美元收購了Global Blood Therapeutics。此次收購加強了公司在稀有血液學領域的影響力。此次收購擴大了輝瑞在鐮狀細胞病領域領先的專業產品組合和管道,其潛在的全球總銷售額峰值超過 30 億美元。 2020 年 10 月,Rygand 以 4.375 億美元現金和每股不可轉讓的業績費權收購了 Pfenex Inc.,即在實現某些裡程碑後獲得 7800 萬美元現金業績費的權利。(CVR)完成了收購.此次收購提供了一個有價值的技術平台,以及與領先製藥公司在治療和疫苗方面的付費合作組合。 2022年6月, BioLineRx 宣布與 GenFleet Therapeutics 達成合作研究協議,開發 Motixafortide 治療胰腺導管腺癌( PDAC )。此次合作建立在 Motixafortide 聯合抗 PD-1 和化療作為轉移性 PDAC 的二線治療的 2a 期 COMBAT/KEYNOTE-202 試驗的積極最終結果的基礎上,以開發這種極具挑戰性的疾病 我們將提供強有力的支持為了繼續

COVID-19 的影響將對全球再生障礙性貧血市場產生積極影響。

COVID-19 疫情對全球再生障礙性貧血市場的增長產生了積極影響。由於再生障礙性貧血的積極治療,免疫抑制具有很高的感染和並發症風險,但如果免疫抑制減少炎症組織的晚期破壞將是有益的。因此,COVID-19 大流行推動了 2020 年再生障礙性貧血的市場價值。

全球再生障礙性貧血市場報告提供大約 69 個市場數據表、60 個數字和 170 頁結構

目錄

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按治療類型劃分的市場細分
  • 按疾病類型劃分的市場細分
  • 按管理途徑劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 全球血液病患者數量不斷增加
      • 癌症患者增加
    • 限制因素
      • 治療費用高
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST 分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求
  • 專利趨勢

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按治療類型

  • 輸血
  • 藥物治療
  • 骨髓輸注

第 8 章按疾病類型

  • 獲得性再生障礙性貧血
  • 遺傳性骨髓衰竭綜合徵

第 9 章給藥途徑

  • 靜脈給藥
  • 口服給藥

第 10 章按銷售渠道

  • 零售藥房
  • 醫院藥房
  • 在線藥店

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 13 章全球再生障礙性貧血市場 - 公司簡介

  • 拜耳公司
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Novartis AG
  • Pfizer Inc.
  • Ligand Pharmceuticals Incorporated
  • Genezyme Corporation
  • Mylan N.V.
  • BIOGEN
  • Otsuka Pharmaceutical Co. Ltd.
  • REGEN BIOPHARMA INC.
  • BiolinRx(*LIST NOT EXHAUSTIVE)

第14章 重要考察

第15章 DataM

簡介目錄
Product Code: DMPH3135

Market Overview

Aplastic Anemia Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

Aplastic anemia is a condition that happens when the body stops generating sufficient new blood cells. The condition leaves a person tired and more prone to uncontrolled bleeding and infections. Aplastic Anemia, a rare and serious condition, may develop at any age. It can happen suddenly or slowly and worsen over time. It can be either moderate or severe. Medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant, may be included in aplastic anemia treatment. The major factors propelling the growth of the aplastic anemia market are the rising number of blood disorder cases worldwide and the rising number of cancer patients globally. Moreover, the technological advancement in aplastic anemia and growing research & development activities in the pharmaceutical sector are further creating a lucrative opportunity for market growth.

Market Dynamics: Rising number of blood disorder cases worldwide drives the market growth

Aplastic anemia is a condition that happens when the body stops generating sufficient new blood cells. The condition leaves a person tired and more prone to uncontrolled bleeding and infections. Aplastic Anemia is a rare and serious condition of the body and may develop at any age. Aplastic anemia can happen suddenly or slowly and worsen over time. Aplastic Anemia can be either moderate or severe. Aplastic Anemia is cured by Medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant. The major factors propelling the growth of the aplastic anemia market are the rising number of blood disorder cases worldwide and the rising number of cancer patients globally. Moreover, the technological advancement in aplastic anemia and growing research & development activities in the pharmaceutical sector are further creating a lucrative opportunity for market growth.

Market Segmentation: The bone marrow transfusion/ stem cell therapy segment is projected to be the dominant segment in the market during the forecast period.

Based on the treatment type, the aplastic anemia market has been classified into bone marrow transfusion/stem cell therapy, blood transfusion and drug therapy.

For decades, hematopoietic stem cell transplantation has been used to treat blood and cardiovascular cell disorders, either unpatched or genetically altered to correct genetic disorders. Also, it is an efficient option for blood disorders with a success rate of over 80%, as per research presented by the American academy of orthopedic surgeons. Thus, rising blood disorders worldwide and efficient usage of stem cells in treating blood disorders are expected to drive the usage of bone marrow transfusion.

Aplastic anemia is segmented based on distribution channel, which includes retail pharmacies, hospitals pharmacies and online pharmacies.

Hospital pharmacies are held a significant market share in the aplastic anemia market. Hospital pharmacies held the dominant position in the global market during the forecast period. A hospital pharmacy is a specialized pharmacy integrated into the medical center's care. These include centers such as a hospital, outpatient clinics, drug-dependent facilities, poison control centers, and a drug information center at a residential care facility. The hospital's pharmacies are expected to gain potential growth in the forthcoming period due to the growing geriatric population and rising number of chronic diseases. Moreover, online pharmacies are expected to project a considerable CAGR during the forecast period. The rising e-commerce sector is expected to propel segment growth in the near future.

Additionally, aplastic anemia is segmented based on disease type, which includes acquired aplastic anemia and inherited bone marrow failure syndromes. Similarly, the route of administration includes intravenous and oral.

Geographical Penetration: North America region is expected to dominate the global aplastic anemia market

Based on geography, the study analyzes the aplastic anemia market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America is holding a dominant position in the global aplastic anemia market in 2021. The U.S. is expected to represent considerable growth in North America during the forecast period. In the U.S., aplastic anemia is expected to have potential growth owing to the high prevalence rate of blood disorders. Moreover, North America is expected to represent significant growth in terms of value during the forecast period. The rise in the prevalence rate of aplastic anemia and bone marrow disorder is expected to propel market growth across the region.

The aplastic anemia market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the growth of the pharmaceutical industry & technological advancement in India and China. Moreover, the increasing population and increasing prevalence of chronic diseases are expected to augment the growth of the Asia Pacific aplastic anemia market.

Competitive Landscape:

The key aplastic anemia players which are contributing to the growth of the global market include Bayer AG, Novartis AG, Pfizer Inc., Ligand Pharmaceuticals Incorporated, Genezyme Corporation, Mylan N.V., BIOGEN, OTSUKA Pharmaceutical Co. Ltd., Regen Biopharma Inc., and BiolinRx, among others. The major players are adopting new product launches and expansion strategies for global growth in the aplastic anemia market. In August 2021, Pfizer acquired Global Blood Therapeutics for $5.4 Billion. This acquisition enhances the company's presence in Rare Hematology. This acquisition expands the leading sickle cell disease expertise portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion. In October 2020, Ligand completed the acquisition of Pfenex Inc. for $437.5 million in cash, plus one non-transferable contingent value right (CVR) per share, representing the right to receive a contingent payment of $78 million in cash if a certain specified milestone is achieved. This acquisition provides a valuable technology platform and portfolio of royalty-bearing collaborations with leading pharmaceutical companies for treatments and vaccines. In June 2022, BioLineRx announced a collaboration agreement with GenFleet Therapeutics to develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC). This collaboration is based on positive final results from Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with anti-PD-1 and chemotherapy as second-line metastatic PDAC therapy, which provides strong support for continued development in this very challenging disease.

COVID-19 Impact: Positive impact on the global aplastic anemia market.

The outbreak of COVID-19 has positively impacted the growth of the aplastic anemia market globally. Since people receive active treatment for aplastic anemia, immunosuppression involves a higher risk of infection and complications; however, it may be beneficial if immunosuppression reduces the late destruction of hyperinflammatory tissue. Therefore, the COVID-19 pandemic drove the market value of the aplastic anemia market in 2020.

The global aplastic anemia market report would provide an access to approximately 69 market data tables, 60 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Treatment Type
  • 3.2. Market Snippet by Disease Type
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising number of blood disorder cases across the world
      • 4.1.1.2. Rising number of cancer patients
    • 4.1.2. Restraint
      • 4.1.2.1. High cost of treatment
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
  • 7.3. Market Attractiveness Index, By Treatment Type Segment
    • 7.3.1. Blood transfusion
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Drug therapy
    • 7.3.3. Bone Marrow Transfusion

8. By Diseases Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
  • 8.3. Market Attractiveness Index, By Diseases Type Segment
    • 8.3.1. Acquired aplastic anemia
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Inherited bone marrow failure syndromes

9. By Route of Administration

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
  • 9.3. Market Attractiveness Index, By Route of Administration Segment
    • 9.3.1. Intravenous
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Oral

10. By Distribution Channel

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 10.3. Market Attractiveness Index, By Distribution Channel Segment
    • 10.3.1. Retail pharmacies
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Hospital pharmacies
    • 10.3.3. Online pharmacies

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Global Aplastic Anemia Market- Company Profiles

  • 13.1. Bayer AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Novartis AG
  • 13.3. Pfizer Inc.
  • 13.4. Ligand Pharmceuticals Incorporated
  • 13.5. Genezyme Corporation
  • 13.6. Mylan N.V.
  • 13.7. BIOGEN
  • 13.8. Otsuka Pharmaceutical Co. Ltd.
  • 13.9. REGEN BIOPHARMA INC.
  • 13.10. BiolinRx (*LIST NOT EXHAUSTIVE)

14. Premium Insights

15. DataM Intelligence Analysis

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us